{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T05:12:56Z","timestamp":1782450776469,"version":"3.54.5"},"reference-count":106,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,24]],"date-time":"2018-08-24T00:00:00Z","timestamp":1535068800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","valueinhealthjournal.com","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.jval.2018.08.003","type":"journal-article","created":{"date-parts":[[2018,9,21]],"date-time":"2018-09-21T14:01:12Z","timestamp":1537538472000},"page":"210-219","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Comparison of Recommendations and Use of Cardiovascular Risk Equations by Health Technology Assessment Agencies and Clinical Guidelines"],"prefix":"10.1016","volume":"22","author":[{"given":"Marissa Blieden","family":"Betts","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Milev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meredith","family":"Hoog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyosung","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Du\u0161an","family":"Milenkovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Hui","family":"Tai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Kutikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Villa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jval.2018.08.003_bib1","doi-asserted-by":"crossref","first-page":"245","DOI":"10.7326\/M14-1753","article-title":"Cardiovascular mortality associated with 5 leading risk factors: national and state preventable fractions estimated from survey data","volume":"163","author":"Patel","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jval.2018.08.003_bib2","volume":"2011","year":"2010"},{"key":"10.1016\/j.jval.2018.08.003_bib3","unstructured":"National Heart Foundation of Australia; Cardiac Society of Australia and New Zealand. Governance document: National Heart Foundation of Australia (NHFA) and Cardiac Society of Australia and New Zealand (CSANZ): Australian Clinical Guidelines for the Management of Acute Coronary Syndromes 2016. Available from: https:\/\/www.heartfoundation.org.au\/images\/uploads\/publications\/PRO-174_ACS_guideline-Governance_document-_FINAL.pdf. [Accessed April 10, 2018]."},{"key":"10.1016\/j.jval.2018.08.003_bib4","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1016\/j.jacc.2013.11.005","article-title":"2013 ACC\/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"63","author":"Goff","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jval.2018.08.003_bib5","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"62","author":"Yancy","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jval.2018.08.003_bib6","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.jacc.2011.02.005","article-title":"Effectiveness-based guidelines for the prevention of cardiovascular disease in women\u20142011 update: a guideline from the American Heart Association","volume":"57","author":"Mosca","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jval.2018.08.003_bib7","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1093\/eurheartj\/ehw106","volume":"37","author":"Piepoli","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jval.2018.08.003_bib8","first-page":"857","article-title":"Simplified lipid guidelines: prevention and management of cardiovascular disease in primary care","volume":"61","author":"Allan","year":"2015","journal-title":"Can Fam Physician"},{"key":"10.1016\/j.jval.2018.08.003_bib9","unstructured":"Tandv\u00e5rds- och l\u00e4kemedelsf\u00f6rm\u00e5nsverket. Drug submission: Repatha (evolocumab). 2016. Available from: https:\/\/www.tlv.se\/download\/18.467926b615d084471ac338a9\/1510316398639\/Underlag_for_beslut160620-repatha.pdf. [Accessed March 29, 2017]."},{"key":"10.1016\/j.jval.2018.08.003_bib10","unstructured":"The Pharmaceutical Benefits Scheme. Drug submission: Exenatide, injection, 5 microgram per dose, 10 microgram per dose, pre-filled pen, 60 doses, Byetta. 2007. Available from: http:\/\/www.pbs.gov.au\/info\/industry\/listing\/elements\/pbac-meetings\/psd\/2007-07\/pbac-psd-exentide-july07. [Accessed March 29, 2017]."},{"key":"10.1016\/j.jval.2018.08.003_bib11","year":"2016","journal-title":"Evolocumab (Repatha) with hypercholesterolemia and mixed dyslipidemia\/homozygous familial hypercholesterolaemia"},{"key":"10.1016\/j.jval.2018.08.003_bib12","unstructured":"Scottish Medicines Consortium. Drug submission: Rosuvastatin, 5mg, 10mg, 20mg, film-coated tablets (Crestor\u00ae) SMC No. (725\/11). 2011. Available from: https:\/\/www.scottishmedicines.org.uk\/files\/advice\/rosuvastatin_Crestor_FINAL_September_2011_for_website.pdf. [Accessed March 29, 2017]."},{"key":"10.1016\/j.jval.2018.08.003_bib13","unstructured":"National Institute for Health and Care Excellence. Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia (review of TA132). 2016. Available from: https:\/\/www.nice.org.uk\/guidance\/TA385\/documents\/committee-papers. [Accessed March 29, 2017]."},{"key":"10.1016\/j.jval.2018.08.003_bib14","year":"2016","journal-title":"Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia"},{"key":"10.1016\/j.jval.2018.08.003_bib15","unstructured":"Pharmaceutical Benefits Advisory Committee. Public Summary Document: Evolocumab 140 mg pre-filled injection pen, Repatha\u00ae, Amgen Pty Ltd. 2015. Available from: www.pbs.gov.au\/industry\/listing\/elements\/pbac-meetings\/psd\/2015-03\/Files\/evolocumab-psd-march-2015.docx. [Accessed April 10, 2018]."},{"key":"10.1016\/j.jval.2018.08.003_bib16","unstructured":"Canadian Agency for Drugs and Technologies in Health. Common Drug Review: Eplerenone (Inspra) (25 mg tablet and 50 mg tablet). 2014. Available from: https:\/\/www.cadth.ca\/sites\/default\/files\/cdr\/pharmacoeconomic\/SR0342_Inspra%20HF_PE_Report_e.pdf. [Accessed April 10, 2018]."},{"key":"10.1016\/j.jval.2018.08.003_bib17","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/clc.22535","article-title":"Cost-effectiveness of LDL-C lowering with evolocumab in patients with high cardiovascular risk in the United States","volume":"39","author":"Gandra","year":"2016","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.jval.2018.08.003_bib18","doi-asserted-by":"crossref","first-page":"d4044","DOI":"10.1136\/bmj.d4044","article-title":"Effectiveness and cost effectiveness of cardiovascular disease prevention in whole populations: modelling study","volume":"343","author":"Barton","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.jval.2018.08.003_bib19","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.jacc.2012.07.029","article-title":"Cost-effectiveness and clinical effectiveness of catheter-based renal denervation for resistant hypertension","volume":"60","author":"Geisler","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jval.2018.08.003_bib20","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1136\/heartjnl-2014-305673","article-title":"Cost-effectiveness of eplerenone in patients with systolic heart failure and mild symptoms","volume":"100","author":"Lee","year":"2014","journal-title":"Heart"},{"key":"10.1016\/j.jval.2018.08.003_bib21","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1001\/jama.2015.6822","article-title":"Cost-effectiveness of 10-year risk thresholds for initiation of statin therapy for primary prevention of cardiovascular disease","volume":"314","author":"Pandya","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.jval.2018.08.003_bib22","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1161\/CIRCOUTCOMES.115.001693","article-title":"Clinical prediction models for cardiovascular disease: Tufts Predictive Analytics and Comparative Effectiveness Clinical Prediction Model Database","volume":"8","author":"Wessler","year":"2015","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.jval.2018.08.003_bib23","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1161\/01.CIR.97.18.1837","article-title":"Prediction of coronary heart disease using risk factor categories","volume":"97","author":"Wilson","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.jval.2018.08.003_bib24","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.107.699579","article-title":"General cardiovascular risk profile for use in primary care: the Framingham Heart Study","volume":"117","author":"D\u2019Agostino","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.jval.2018.08.003_bib25","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1161\/01.STR.25.1.40","article-title":"Stroke risk profile: adjustment for antihypertensive medication. The Framingham Study","volume":"25","author":"D\u2019Agostino","year":"1994","journal-title":"Stroke"},{"key":"10.1016\/j.jval.2018.08.003_bib26","unstructured":"The Pharmaceutical Benefits Scheme. Drug submission: Sibutramine hydrochloride, capsules, 10 mg and 15 mg, Reductil\/Ectiva. 2006. Available from: http:\/\/www.pbs.gov.au\/info\/industry\/listing\/elements\/pbac-meetings\/psd\/2006-11\/pbac-psd-sibutramine-nov06. [Accessed March 29, 2017]."},{"key":"10.1016\/j.jval.2018.08.003_bib27","unstructured":"The Pharmaceutical Benefits Scheme. Drug submission: Nicotinic acid, tablets (prolonged release), 500 mg, 750 mg and 1 g, Niaspan\u00ae. 2006. Available from: http:\/\/www.pbs.gov.au\/info\/industry\/listing\/elements\/pbac-meetings\/psd\/2006-07\/nicotinic. [Accessed March 29, 2017]."},{"key":"10.1016\/j.jval.2018.08.003_bib28","unstructured":"The Pharmaceutical Benefits Scheme. Drug submission: Sibutramine hydrochloride, capsules, 10 mg and 15 mg, Reductil\/Ectiva. 2008. Available from: http:\/\/www.pbs.gov.au\/info\/industry\/listing\/elements\/pbac-meetings\/psd\/2008-03\/pbac-psd-sibutramine-hydrochloride-mar08. [Accessed March 29, 2017]."},{"key":"10.1016\/j.jval.2018.08.003_bib29","unstructured":"National Institute for Health and Care Excellence. Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia. Technology appraisal guidance [TA394]. 2016. Available from: https:\/\/www.nice.org.uk\/guidance\/ta394\/. [Accessed March 29, 2017]."},{"key":"10.1016\/j.jval.2018.08.003_bib30","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials","volume":"380","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jval.2018.08.003_bib31","unstructured":"National Institute for Health and Care Excellence. Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease [CG181]. 2014. Available from: http:\/\/www.nice.org.uk\/Guidance\/CG181. [Accessed March 29, 2017]."},{"key":"10.1016\/j.jval.2018.08.003_bib32","unstructured":"Wisl\u00f8ff T, Selmer RM, Halvorsen S, Kristiansen IS. Norwegian Cardiovascular Disease Model (NorCaD)\u2014a simulation model for estimating health benefits and cost consequences of cardiovascular interventions. Rapport fra Kunnskapssenteret nr. 23\u20132008. 2008. Available from: https:\/\/www.fhi.no\/globalassets\/kss\/filer\/filer\/publikasjoner\/rapporter\/20082\/rapport_0823_norcad30.pdf. [Accessed March 29, 2017]."},{"key":"10.1016\/j.jval.2018.08.003_bib33","series-title":"Rapid Assessment: Cardiovascular Primary Prevention in the Belgian General Practice","year":"2007"},{"key":"10.1016\/j.jval.2018.08.003_bib34","article-title":"Risk estimation and the prevention of cardiovascular disease","year":"2007","journal-title":"A national clinical guideline 97"},{"key":"10.1016\/j.jval.2018.08.003_bib35","unstructured":"Basque Health System\u2014Osakidetza. Clinical practice guideline on the management of lipids as a cardiovascular risk factor. 2008. Available from: https:\/\/www.guideline.gov\/summaries\/summary\/15711?search=risk%20assessment. [Accessed March 29, 2017]."},{"key":"10.1016\/j.jval.2018.08.003_bib36","unstructured":"Basque Health System\u2014Osakidetza. Clinical practice guidelines on arterial hypertension. 2007 update. 2008. Available from: https:\/\/www.guideline.gov\/summaries\/summary\/15712?search=risk%20assessment. [Accessed March 29, 2017]."},{"key":"10.1016\/j.jval.2018.08.003_bib37","unstructured":"CPG Programme for the NHS. Screening and treatment of macrovascular complications. Cinical Practice Guideline for type 2 diabetes. 2012. Available from: http:\/\/www.guiasalud.es\/egpc\/traduccion\/ingles\/diabetes\/completa\/apartado09\/cribado_tratamiento_macrovasculares.html [Accessed March 29, 2017]."},{"key":"10.1016\/j.jval.2018.08.003_bib38","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.cjca.2012.11.032","article-title":"2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult","volume":"29","author":"Anderson","year":"2013","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.jval.2018.08.003_bib39","unstructured":"American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists\u2019 guidelines for management of dyslipidemia and prevention of atherosclerosis. 2012. Available from: http:\/\/journals.aace.com\/doi\/pdf\/10.4158\/EP.18.S1.1. [Accessed March 29, 2017]."},{"key":"10.1016\/j.jval.2018.08.003_bib40","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.amepre.2010.11.021","article-title":"Atherosclerotic cardiovascular disease screening in adults: American College of Preventive Medicine position statement on preventive practice","volume":"40","author":"Lim","year":"2011","journal-title":"Am J Prev Med"},{"key":"10.1016\/j.jval.2018.08.003_bib41","doi-asserted-by":"crossref","unstructured":"Vandvik PO, Lincoff AM, Gore JM, et\u00a0al. Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2):e637S\u2013668.","DOI":"10.1378\/chest.141.4.1129c"},{"key":"10.1016\/j.jval.2018.08.003_bib42","unstructured":"Department of Veterans Affairs; Department of Defense. VA\/DoD clinical practice guideline for the management of dyslipidemia for cardiovascular risk reduction. 2014. Available from: https:\/\/www.healthquality.va.gov\/guidelines\/CD\/lipids\/VADoDDyslipidemiaCPG2014.pdf. [Accessed March 29, 2017]."},{"key":"10.1016\/j.jval.2018.08.003_bib43","first-page":"512","article-title":"Screening for coronary\u00a0heart disease with electrocardiography: U.S. Preventive Services Task Force recommendation statement","volume":"157","author":"Moyer","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jval.2018.08.003_bib44","unstructured":"US Preventive Services Task Force. Behavioral counseling interventions to promote a healthful diet and physical activity for cardiovascular disease prevention in adults: U.S. Preventive Services Task Force recommendation statement. 2012. Available from: https:\/\/www.uspreventiveservicestaskforce.org\/Home\/GetFile\/1\/1720\/physrs\/pdf. [Accessed March 29, 2017]."},{"key":"10.1016\/j.jval.2018.08.003_bib45","first-page":"427","article-title":"Spanish adaptation of the European Guide to Cardiovascular Prevention (I) [Spanish]","volume":"34","author":"Brotons","year":"2004","journal-title":"Aten Primaria"},{"key":"10.1016\/j.jval.2018.08.003_bib46","first-page":"37","article-title":"Guidelines on cardiovascular disease prevention in clinical practice. Belgian Working Group on Cardiovascular Prevention and Rehabilitation [French]","volume":"30","author":"Dereppe","year":"2009","journal-title":"Rev Med Brux"},{"key":"10.1016\/j.jval.2018.08.003_bib47","year":"2006","journal-title":"Cardiovascular risk management"},{"key":"10.1016\/j.jval.2018.08.003_bib48","first-page":"II","article-title":"Czech Atherosclerosis Society guidelines for the diagnosis and treatment of dyslipidemia in adults [Czech]","volume":"146","author":"Vaverkova","year":"2007","journal-title":"Cas Lek Cesk"},{"key":"10.1016\/j.jval.2018.08.003_bib49","year":"2013","journal-title":"Non-invasive markers of subclinical atherosclerosis for predicting a primary cardiovascular event: a rapid systematic review"},{"key":"10.1016\/j.jval.2018.08.003_bib50","unstructured":"Federaal Kenniscentrum\u2014Centre f\u00e9d\u00e9ral d\u2019expertise. Novel serum biomarkers for the prediction of cardiovascular risk synthesis. 2015. Available from: https:\/\/kce.fgov.be\/sites\/default\/files\/atoms\/files\/KCE_201_Novel_serum_biomarkers_for_the_prediction_of_cardiovascular_risk.pdf. [Accessed March 29, 2017]."},{"key":"10.1016\/j.jval.2018.08.003_bib51","unstructured":"Tandv\u00e5rds- och l\u00e4kemedelsf\u00f6rm\u00e5nsverket. A review of medicines that lower blood pressure [En genomg\u00e5ng av de l\u00e4kemedel som s\u00e4nker blodtrycket]. 2008. Available from: https:\/\/www.tlv.se\/download\/18.467926b615d084471ac33e28\/1510316368904\/rapport-blodtryck.pdf. [Accessed March 29, 2017]."},{"key":"10.1016\/j.jval.2018.08.003_bib52","unstructured":"Tandv\u00e5rds- och l\u00e4kemedelsf\u00f6rm\u00e5nsverket. The review of drugs for lipid disorders [Genomg\u00e5ngen av l\u00e4kemedel vid blodfettrubbningar]. 2009. Available from: https:\/\/www.tlv.se\/download\/18.467926b615d084471ac33ed5\/1510316365043\/slutrapport-blodfett.pdf. [Accessed March 29, 2017]."},{"key":"10.1016\/j.jval.2018.08.003_bib53","unstructured":"Zorginstituut Nederland. Drug submission: Pravastatin\/fenofibrate (Pravafenix) at dyslipidemia with high triglyceride concentration. 2012. Available from: https:\/\/www.zorginstituutnederland.nl\/publicaties\/rapport\/2012\/10\/29\/pravastatine-fenofibraat-pravafenix-bij-dyslipidemie-met-hoge-concentratie-triglyceriden. [Accessed March 29, 2017]."},{"key":"10.1016\/j.jval.2018.08.003_bib54","unstructured":"Scottish Medicines Consortium. Drug submission: Evolocumab, 140mg, solution for injection in pre-filled pen (Repatha\u00ae Sureclick) or pre-filled syringe (Repatha\u00ae PFS) SMC No. (1148\/16). 2016. Available from: https:\/\/www.scottishmedicines.org.uk\/files\/advice\/DAD_evolocumab_Repatha_FINAL_May_2016_for_website.pdf. [Accessed March 29, 2017]."},{"key":"10.1016\/j.jval.2018.08.003_bib55","unstructured":"Canadian Agency for Drugs and Technologies in Health. Economic evaluation: third-line therapy for patients with type 2 diabetes inadequately controlled with metformin and sulfonylurea combination therapy. 2010. Available from: https:\/\/www.cadth.ca\/sites\/default\/files\/pdf\/Diabetes_TR_Economic_Evaluation_Final_e.pdf. [Accessed March 29, 2017]."},{"key":"10.1016\/j.jval.2018.08.003_bib56","unstructured":"The Pharmaceutical Benefits Scheme. Drug submission: Rosiglitazone maleate, tablet, 4 mg (base) and 8 mg Avandia; and rosiglitazone maleate with metformin hydrochloride, 2 mg (base)\u2013500 mg, 2 mg (base)\u20131 g, 4 mg (base)\u2013500 mg and 4 mg (base)\u20131 g, Avandamet. 2007. Available from: http:\/\/www.pbs.gov.au\/info\/industry\/listing\/elements\/pbac-meetings\/psd\/2007-11\/pbac-psd-rosiglitazone-nov07. [Accessed March 29, 2017]."},{"key":"10.1016\/j.jval.2018.08.003_bib57","unstructured":"The Pharmaceutical Benefits Scheme. Drug submission: Liraglutide (rys), solution for injection, 3 mL pre-filled injection pen, 6 mg per mL, Victoza\u00ae. 2010. Available from: http:\/\/www.pbs.gov.au\/info\/industry\/listing\/elements\/pbac-meetings\/psd\/2010-11\/pbac-psd-Liraglutide-nov10. [Accessed March 29, 2017]."},{"key":"10.1016\/j.jval.2018.08.003_bib58","unstructured":"The Pharmaceutical Benefits Scheme. Drug submission: Exenatide, powder for injection, 2 mg, Bydureon\u00ae. 2013. Available from: http:\/\/www.pbs.gov.au\/info\/industry\/listing\/elements\/pbac-meetings\/psd\/2013-11\/exenatide. [Accessed March 29, 2017]."},{"key":"10.1016\/j.jval.2018.08.003_bib59","unstructured":"The Pharmaceutical Benefits Scheme. Exenatide, powder for injection, 2 mg, Bydureon\u00ae Public Summary Document. 2011. Available from: http:\/\/www.pbs.gov.au\/info\/industry\/listing\/elements\/pbac-meetings\/psd\/2011-07\/pbac-psd-exenatide-july-11. [Accessed March 29, 2017]."},{"key":"10.1016\/j.jval.2018.08.003_bib60","unstructured":"Basque Office for Health Technology Assessment; Working Group of the Clinical Practice Guideline on Type 2 Diabetes. Clinical Practice Guideline for type 2 diabetes. 2008. Available from: http:\/\/www.guiasalud.es\/egpc\/traduccion\/ingles\/diabetes\/completa\/apartado09\/cribado_tratamiento_macrovasculares.html. [Accessed March 29, 2017]."},{"key":"10.1016\/j.jval.2018.08.003_bib61","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1161\/01.CIR.95.12.2660","article-title":"Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation","volume":"95","author":"Aaronson","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.jval.2018.08.003_bib62","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1161\/CIRCHEARTFAILURE.109.932996","article-title":"Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE)","volume":"4","author":"Komajda","year":"2011","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jval.2018.08.003_bib63","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1161\/CIRCULATIONAHA.105.584102","article-title":"The Seattle Heart Failure Model: prediction of survival in heart failure","volume":"113","author":"Levy","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.jval.2018.08.003_bib64","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1093\/eurheartj\/ehi555","article-title":"Predictors of mortality and morbidity in patients with chronic heart failure","volume":"27","author":"Pocock","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jval.2018.08.003_bib65","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1093\/eurjhf\/hfn046","article-title":"Predictors of fatal and non-fatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein A-1, high-sensitivity C-reactive peptide and N-terminal pro B-type natriuretic peptide","volume":"11","author":"Wedel","year":"2009","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jval.2018.08.003_bib66","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1001\/jama.293.5.572","article-title":"Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis","volume":"293","author":"Fonarow","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.jval.2018.08.003_bib67","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1161\/CIRCHEARTFAILURE.111.962290","article-title":"Admission, discharge, or change in B-type natriuretic peptide and long-term outcomes: data from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF) linked to Medicare claims","volume":"4","author":"Kociol","year":"2011","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jval.2018.08.003_bib68","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1001\/jama.290.19.2581","article-title":"Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model","volume":"290","author":"Lee","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.jval.2018.08.003_bib69","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.jacc.2009.08.083","article-title":"Triage after hospitalization with advanced heart failure: the ESCAPE (Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness) risk model and discharge score","volume":"55","author":"O\u2019Connor","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jval.2018.08.003_bib70","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1161\/CIRCOUTCOMES.109.854877","article-title":"A validated risk score for in-hospital mortality in patients with heart failure from the American Heart Association Get With the Guidelines program","volume":"3","author":"Peterson","year":"2010","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.jval.2018.08.003_bib71","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1007\/s00125-004-1527-z","article-title":"A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68)","volume":"47","author":"Clarke","year":"2004","journal-title":"Diabetologia"},{"key":"10.1016\/j.jval.2018.08.003_bib72","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1161\/01.STR.0000020091.07144.C7","article-title":"UKPDS 60: risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine","volume":"33","author":"Kothari","year":"2002","journal-title":"Stroke"},{"key":"10.1016\/j.jval.2018.08.003_bib73","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2337\/diacare.27.1.201","article-title":"Risk factors for myocardial infarction case fatality and stroke case fatality in type 2 diabetes: UKPDS 66","volume":"27","author":"Stevens","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jval.2018.08.003_bib74","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1042\/cs1010671","article-title":"The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56)","volume":"101","author":"Stevens","year":"2001","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.jval.2018.08.003_bib75","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1136\/emj.2006.041624","article-title":"Can the ABCD score be dichotomised to identify high-risk patients with transient ischaemic attack in the emergency department?","volume":"24","author":"Bray","year":"2007","journal-title":"Emerg Med J"},{"key":"10.1016\/j.jval.2018.08.003_bib76","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1136\/bmj.38603.656076.63","article-title":"Risk score for predicting death, myocardial infarction, and stroke in patients with stable angina, based on a large randomised trial cohort of patients","volume":"331","author":"Clayton","year":"2005","journal-title":"BMJ"},{"key":"10.1016\/j.jval.2018.08.003_bib77","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1136\/bmj.38695.605440.AE","article-title":"Predicting prognosis in stable angina\u2014results from the Euro heart survey of stable angina: prospective observational study","volume":"332","author":"Daly","year":"2006","journal-title":"BMJ"},{"key":"10.1016\/j.jval.2018.08.003_bib78","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.amjmed.2012.01.014","article-title":"An international model to predict recurrent cardiovascular disease","volume":"125","author":"Wilson","year":"2012","journal-title":"Am J Med"},{"key":"10.1016\/j.jval.2018.08.003_bib79","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1001\/jama.291.22.2727","article-title":"A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry","volume":"291","author":"Eagle","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.jval.2018.08.003_bib80","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1136\/bmj.38985.646481.55","article-title":"Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE)","volume":"333","author":"Fox","year":"2006","journal-title":"BMJ"},{"key":"10.1016\/j.jval.2018.08.003_bib81","doi-asserted-by":"crossref","first-page":"e004425","DOI":"10.1136\/bmjopen-2013-004425","article-title":"Should patients with acute coronary disease be stratified for management according to their risk? Derivation, external validation and outcomes using the updated GRACE risk score","volume":"4","author":"Fox","year":"2014","journal-title":"BMJ Open"},{"key":"10.1016\/j.jval.2018.08.003_bib82","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1161\/01.CIR.101.19.2231","article-title":"Prediction of 1-year survival after thrombolysis for acute myocardial infarction in the global utilization of streptokinase and TPA for occluded coronary arteries trial","volume":"101","author":"Califf","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.jval.2018.08.003_bib83","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0735-1097(01)01395-X","article-title":"Predicting one-year mortality among elderly survivors of hospitalization for an acute myocardial infarction: results from the Cooperative Cardiovascular Project","volume":"38","author":"Krumholz","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jval.2018.08.003_bib84","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1001\/jama.284.7.835","article-title":"The TIMI risk score for unstable angina\/non-ST elevation MI: a method for prognostication and therapeutic decision making","volume":"284","author":"Antman","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.jval.2018.08.003_bib85","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1161\/01.CIR.102.17.2031","article-title":"TIMI risk score for ST-elevation myocardial infarction: a convenient, bedside, clinical score for risk assessment at presentation: an intravenous nPA for treatment of infarcting myocardium early II trial substudy","volume":"102","author":"Morrow","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.jval.2018.08.003_bib86","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1161\/01.CIR.100.6.599","article-title":"PREDICT: a simple risk score for clinical severity and long-term prognosis after hospitalization for acute myocardial infarction or unstable angina: the Minnesota Heart Survey","volume":"100","author":"Jacobs","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.jval.2018.08.003_bib87","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/clc.22428","article-title":"Burden of first and recurrent cardiovascular events among patients with hyperlipidemia","volume":"38","author":"Punekar","year":"2015","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.jval.2018.08.003_bib88","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/aje\/kwh189","article-title":"Prediction of ischemic stroke risk in the Atherosclerosis Risk in Communities Study","volume":"160","author":"Chambless","year":"2004","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.jval.2018.08.003_bib89","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1136\/hrt.2006.108167","article-title":"Adding social deprivation and family history to cardiovascular risk assessment: the ASSIGN score from the Scottish Heart Health Extended Cohort (SHHEC)","volume":"93","author":"Woodward","year":"2007","journal-title":"Heart"},{"key":"10.1016\/j.jval.2018.08.003_bib90","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1001\/archinte.158.6.655","article-title":"Estimating the benefits of modifying risk factors of cardiovascular disease: a comparison of primary vs secondary prevention","volume":"158","author":"Grover","year":"1998","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jval.2018.08.003_bib91","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0895-4356(01)00434-6","article-title":"A stroke prediction score in the elderly: validation and Web-based application","volume":"55","author":"Lumley","year":"2002","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jval.2018.08.003_bib92","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1093\/ije\/dyh405","article-title":"Prediction of coronary events in a low incidence population: assessing accuracy of the CUORE Cohort Study prediction equation","volume":"34","author":"Ferrario","year":"2005","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.jval.2018.08.003_bib93","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1161\/01.STR.29.7.1341","article-title":"Risk factors for ischemic stroke: Dubbo Study of the elderly","volume":"29","author":"Simons","year":"1998","journal-title":"Stroke"},{"issue":"Suppl. 1","key":"10.1016\/j.jval.2018.08.003_bib94","doi-asserted-by":"crossref","first-page":"i30","DOI":"10.1136\/jech.56.suppl_1.i30","article-title":"Prediction of stroke in the general population in Europe (EUROSTROKE): Is there a role for fibrinogen and electrocardiography?","volume":"56","author":"Moons","year":"2002","journal-title":"J Epidemiol Community Health"},{"key":"10.1016\/j.jval.2018.08.003_bib95","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S2213-8587(15)00081-9","article-title":"A novel risk score to predict cardiovascular disease risk in national populations (Globorisk): a pooled analysis of prospective cohorts and health examination surveys","volume":"3","author":"Hajifathalian","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jval.2018.08.003_bib96","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/BF03086144","article-title":"Chest pain in the emergency room: value of the HEART score","volume":"16","author":"Six","year":"2008","journal-title":"Neth Heart J"},{"key":"10.1016\/j.jval.2018.08.003_bib97","first-page":"286","article-title":"Model for estimation of cardiovascular risk in Norway [Norwegian]","volume":"128","author":"Selmer","year":"2008","journal-title":"Tidsskr Nor Laegeforen"},{"key":"10.1016\/j.jval.2018.08.003_bib98","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1161\/hc0302.102575","article-title":"Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study","volume":"105","author":"Assmann","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jval.2018.08.003_bib99","doi-asserted-by":"crossref","first-page":"c6624","DOI":"10.1136\/bmj.c6624","article-title":"Derivation, validation, and evaluation of a new QRISK model to estimate lifetime risk of cardiovascular disease: cohort study using QResearch database","volume":"341","author":"Hippisley-Cox","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.jval.2018.08.003_bib100","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1136\/bmj.39609.449676.25","article-title":"Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2","volume":"336","author":"Hippisley-Cox","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.jval.2018.08.003_bib101","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1161\/CIRCULATIONAHA.108.814251","article-title":"C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men","volume":"118","author":"Ridker","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.jval.2018.08.003_bib102","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1001\/jama.297.6.611","article-title":"Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score","volume":"297","author":"Ridker","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.jval.2018.08.003_bib103","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0195-668X(03)00114-3","article-title":"Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project","volume":"24","author":"Conroy","year":"2003","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jval.2018.08.003_bib104","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.2337\/dc05-1911","article-title":"Derivation and validation of a prediction score for major coronary heart disease events in a U.K. type 2 diabetic population","volume":"29","author":"Donnan","year":"2006","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jval.2018.08.003_bib105","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1007\/s00125-004-1574-5","article-title":"Prediction of the risk of cardiovascular mortality using a score that includes glucose as a risk factor. The DECODE Study","volume":"47","author":"Balkau","year":"2004","journal-title":"Diabetologia"},{"key":"10.1016\/j.jval.2018.08.003_bib106","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.2337\/dc08-0662","article-title":"Risk prediction of cardiovascular disease in type 2 diabetes: a risk equation from the Swedish National Diabetes Register","volume":"31","author":"Cederholm","year":"2008","journal-title":"Diabetes Care"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301518332650?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301518332650?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,24]],"date-time":"2019-10-24T15:13:24Z","timestamp":1571930004000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301518332650"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":106,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["S1098301518332650"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2018.08.003","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of Recommendations and Use of Cardiovascular Risk Equations by Health Technology Assessment Agencies and Clinical Guidelines","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2018.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 ISPOR-The Professional Society for Health Economics and Outcomes Research. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}